The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design
Overview
Authors
Affiliations
Background: Heart failure (HF) with preserved ejection fraction (EF) accounts for a substantial proportion of cases of HF, and to date no treatments have clearly improved outcome. There are also little data comparing HF cohorts of differing ethnicity within the Asia-Pacific region.
Methods: The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study are parallel prospective studies using identical protocols to enroll patients with HF across 6 centers in Singapore and 4 in New Zealand. The objectives are to determine the relative prevalence, characteristics, and outcomes of patients with HF and preserved EF (EF ≥50%) compared with those with HF and reduced EF, and to determine initial data on ethnic differences within and between New Zealand and Singapore. Case subjects (n = 2,500) are patients hospitalized with a primary diagnosis of HF or attending outpatient clinics for management of HF within 6 months of HF decompensation. Control subjects are age- and gender-matched community-based adults without HF from Singapore (n = 1,250) and New Zealand (n = 1,073). All participants undergo detailed clinical assessment, echocardiography, and blood biomarker measurements at baseline, 6 weeks, and 6 months, and are followed over 2 years for death or hospitalization. Substudies include vascular assessment, cardiopulmonary exercise testing, retinal imaging, and cardiac magnetic resonance imaging.
Conclusions: The SHOP and PEOPLE studies are the first prospective multicenter studies defining the epidemiology and interethnic differences among patients with HF in the Asia-Oceanic region, and will provide unique insights into the pathophysiology and outcomes for these patients.
Chen N, Tan M, Xu J, Zuo L, Dong Y Stroke Vasc Neurol. 2024; 10(1):25-31.
PMID: 38649196 PMC: 11877426. DOI: 10.1136/svn-2023-002701.
Teramoto K, Ouwerkerk W, Tay W, Tromp J, Teng T, Chandramouli C JACC Asia. 2023; 3(5):739-751.
PMID: 38095008 PMC: 10715881. DOI: 10.1016/j.jacasi.2023.06.007.
Endotrophin, a Collagen VI Formation-Derived Peptide, in Heart Failure.
Chirinos J, Zhao L, Reese-Petersen A, Cohen J, Genovese F, Richards A NEJM Evid. 2023; 1(10).
PMID: 37645406 PMC: 10465122. DOI: 10.1056/evidoa2200091.
Heart Failure and Multimorbidity in Asia.
Ang N, Chandramouli C, Yiu K, Lawson C, Tromp J Curr Heart Fail Rep. 2023; 20(1):24-32.
PMID: 36811820 PMC: 9977703. DOI: 10.1007/s11897-023-00585-2.
Teng T, Tay W, Ouwerkerk W, Tromp J, Richards A, Gamble G ESC Heart Fail. 2023; 10(2):1280-1293.
PMID: 36722315 PMC: 10053276. DOI: 10.1002/ehf2.14275.